nodes	percent_of_prediction	percent_of_DWPC	metapath
Melphalan—Chlorambucil—hematologic cancer	0.309	1	CrCtD
Melphalan—Ibuprofen—Procarbazine—hematologic cancer	0.108	1	CrCrCtD
Melphalan—Alkylating Activity—Busulfan—hematologic cancer	0.0745	0.165	CiPCiCtD
Melphalan—Alkylating Activity—Procarbazine—hematologic cancer	0.0565	0.125	CiPCiCtD
Melphalan—Alkylating Activity—Mechlorethamine—hematologic cancer	0.0565	0.125	CiPCiCtD
Melphalan—Alkylating Activity—Lomustine—hematologic cancer	0.0565	0.125	CiPCiCtD
Melphalan—Alkylating Activity—Ifosfamide—hematologic cancer	0.048	0.107	CiPCiCtD
Melphalan—Alkylating Activity—Chlorambucil—hematologic cancer	0.0428	0.0949	CiPCiCtD
Melphalan—Alkylating Activity—Thiotepa—hematologic cancer	0.0428	0.0949	CiPCiCtD
Melphalan—Alkylating Activity—Carmustine—hematologic cancer	0.0392	0.0868	CiPCiCtD
Melphalan—Alkylating Activity—Dacarbazine—hematologic cancer	0.0342	0.0759	CiPCiCtD
Melphalan—SLC22A3—Irinotecan—hematologic cancer	0.0203	0.534	CbGbCtD
Melphalan—SLC22A3—Vincristine—hematologic cancer	0.0177	0.466	CbGbCtD
Melphalan—SLC7A5—Basigin interactions—SPN—hematologic cancer	0.00142	0.0821	CbGpPWpGaD
Melphalan—SLC22A3—Abacavir transmembrane transport—SLC22A1—hematologic cancer	0.000886	0.0513	CbGpPWpGaD
Melphalan—SLC22A3—Abacavir transmembrane transport—ABCG2—hematologic cancer	0.00079	0.0457	CbGpPWpGaD
Melphalan—SLC7A5—hematopoietic system—hematologic cancer	0.000786	0.151	CbGeAlD
Melphalan—SLC7A5—Basigin interactions—ATP1B1—hematologic cancer	0.000766	0.0443	CbGpPWpGaD
Melphalan—SLC22A3—Organic cation transport—SLC22A1—hematologic cancer	0.000609	0.0352	CbGpPWpGaD
Melphalan—SLC7A5—gonad—hematologic cancer	0.000597	0.115	CbGeAlD
Melphalan—L-DOPA—PSIP1—hematologic cancer	0.000535	0.442	CrCbGaD
Melphalan—SLC7A5—blood—hematologic cancer	0.000521	0.0999	CbGeAlD
Melphalan—SLC22A3—Abacavir transport and metabolism—SLC22A1—hematologic cancer	0.000509	0.0295	CbGpPWpGaD
Melphalan—SLC7A5—bone marrow—hematologic cancer	0.000504	0.0967	CbGeAlD
Melphalan—SLC22A3—Abacavir transmembrane transport—ABCB1—hematologic cancer	0.000493	0.0285	CbGpPWpGaD
Melphalan—SLC22A3—hematopoietic system—hematologic cancer	0.000488	0.0936	CbGeAlD
Melphalan—Chlorambucil—GSTP1—hematologic cancer	0.000486	0.401	CrCbGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—SPN—hematologic cancer	0.000472	0.0273	CbGpPWpGaD
Melphalan—SLC7A5—lung—hematologic cancer	0.000456	0.0876	CbGeAlD
Melphalan—SLC22A3—Abacavir transport and metabolism—ABCG2—hematologic cancer	0.000454	0.0263	CbGpPWpGaD
Melphalan—SLC7A5—testis—hematologic cancer	0.000431	0.0827	CbGeAlD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—CD2—hematologic cancer	0.00042	0.0243	CbGpPWpGaD
Melphalan—SLC22A3—Organic cation/anion/zwitterion transport—SLC22A1—hematologic cancer	0.000413	0.0239	CbGpPWpGaD
Melphalan—SLC22A3—gonad—hematologic cancer	0.000371	0.0712	CbGeAlD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—CD58—hematologic cancer	0.000358	0.0207	CbGpPWpGaD
Melphalan—SLC7A5—Isotretinoin—Alitretinoin—hematologic cancer	0.000353	0.376	CbGdCrCtD
Melphalan—SLC7A5—Tretinoin—Alitretinoin—hematologic cancer	0.000353	0.376	CbGdCrCtD
Melphalan—SLC7A5—lymph node—hematologic cancer	0.000312	0.0599	CbGeAlD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUND—hematologic cancer	0.000303	0.0175	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—UGT1A1—hematologic cancer	0.000303	0.0175	CbGpPWpGaD
Melphalan—SLC22A3—lung—hematologic cancer	0.000283	0.0544	CbGeAlD
Melphalan—SLC22A3—Abacavir transport and metabolism—ABCB1—hematologic cancer	0.000283	0.0164	CbGpPWpGaD
Melphalan—SLC22A3—testis—hematologic cancer	0.000267	0.0513	CbGeAlD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ATP1B1—hematologic cancer	0.000255	0.0147	CbGpPWpGaD
Melphalan—SLC7A5—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—hematologic cancer	0.00025	0.0144	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—NQO1—hematologic cancer	0.000208	0.012	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ITGAX—hematologic cancer	0.000196	0.0113	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—HSP90AA1—hematologic cancer	0.000195	0.0113	CbGpPWpGaD
Melphalan—SLC22A3—lymph node—hematologic cancer	0.000194	0.0372	CbGeAlD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—SELL—hematologic cancer	0.000188	0.0109	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ITGAL—hematologic cancer	0.000161	0.00933	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—HES1—hematologic cancer	0.00016	0.00927	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—BAX—hematologic cancer	0.000155	0.00898	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—EHD3—hematologic cancer	0.00015	0.00871	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—LCK—hematologic cancer	0.000128	0.00742	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SPN—hematologic cancer	0.000128	0.0074	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	0.000125	0.00724	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CD2—hematologic cancer	0.000114	0.0066	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—ITGA4—hematologic cancer	0.000113	0.00651	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—CD44—hematologic cancer	0.000113	0.00651	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	0.000112	0.00646	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—THPO—hematologic cancer	9.69e-05	0.00561	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CD58—hematologic cancer	9.69e-05	0.00561	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—GRB2—hematologic cancer	9.54e-05	0.00552	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IFNG—hematologic cancer	9.36e-05	0.00542	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—AQP9—hematologic cancer	9.03e-05	0.00522	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SRGN—hematologic cancer	8.64e-05	0.005	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—CDKN1B—hematologic cancer	8.5e-05	0.00492	CbGpPWpGaD
Melphalan—Ibuprofen—BCL2—hematologic cancer	8.43e-05	0.0696	CrCbGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—FXYD6—hematologic cancer	8.39e-05	0.00486	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL1B—hematologic cancer	8.35e-05	0.00483	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—IL2—hematologic cancer	8.32e-05	0.00482	CbGpPWpGaD
Melphalan—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A1—hematologic cancer	8.27e-05	0.00479	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MPL—hematologic cancer	8.24e-05	0.00477	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—JUN—hematologic cancer	8.09e-05	0.00468	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—S100A10—hematologic cancer	7.9e-05	0.00457	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GATA2—hematologic cancer	7.61e-05	0.0044	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—EP300—hematologic cancer	7.46e-05	0.00432	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	7.38e-05	0.00427	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—SRC—hematologic cancer	7.26e-05	0.0042	CbGpPWpGaD
Melphalan—Ibuprofen—UGT1A1—hematologic cancer	7.17e-05	0.0592	CrCbGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—NUP98—hematologic cancer	6.96e-05	0.00403	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ATP1B1—hematologic cancer	6.91e-05	0.004	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—S100A10—hematologic cancer	6.84e-05	0.00396	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—NUP214—hematologic cancer	6.71e-05	0.00388	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—FN1—hematologic cancer	6.69e-05	0.00387	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GATA1—hematologic cancer	6.55e-05	0.00379	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—TGFB1—hematologic cancer	6.49e-05	0.00376	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	6.37e-05	0.00369	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	6.36e-05	0.00368	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PTPN11—hematologic cancer	6.29e-05	0.00364	CbGpPWpGaD
Melphalan—SLC7A5—Aryl Hydrocarbon Receptor Pathway—TNF—hematologic cancer	6.06e-05	0.00351	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ANXA2—hematologic cancer	5.99e-05	0.00347	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	5.98e-05	0.00346	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	5.68e-05	0.00329	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	5.67e-05	0.00328	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GNA13—hematologic cancer	5.57e-05	0.00322	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3R1—hematologic cancer	5.32e-05	0.00308	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITGAX—hematologic cancer	5.31e-05	0.00307	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—JAK3—hematologic cancer	5.31e-05	0.00307	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CD9—hematologic cancer	5.23e-05	0.00303	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—F3—hematologic cancer	5.23e-05	0.00303	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ANXA2—hematologic cancer	5.18e-05	0.003	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SGK1—hematologic cancer	5.18e-05	0.003	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ATP4A—hematologic cancer	5.18e-05	0.003	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SELL—hematologic cancer	5.09e-05	0.00295	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL3RA—hematologic cancer	4.96e-05	0.00287	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CB—hematologic cancer	4.91e-05	0.00284	CbGpPWpGaD
Melphalan—SLC7A5—Desoximetasone—Betamethasone—hematologic cancer	4.81e-05	0.0514	CbGdCrCtD
Melphalan—SLC7A5—Desoximetasone—Dexamethasone—hematologic cancer	4.81e-05	0.0514	CbGdCrCtD
Melphalan—SLC7A5—Desoximetasone—Triamcinolone—hematologic cancer	4.7e-05	0.0502	CbGdCrCtD
Melphalan—SLC7A5—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	4.67e-05	0.0027	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—AQP9—hematologic cancer	4.6e-05	0.00266	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—FGR—hematologic cancer	4.54e-05	0.00263	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—H3F3B—hematologic cancer	4.54e-05	0.00263	CbGpPWpGaD
Melphalan—SLC7A5—Desoximetasone—Prednisone—hematologic cancer	4.46e-05	0.0477	CbGdCrCtD
Melphalan—SLC7A5—Hemostasis—MYB—hematologic cancer	4.37e-05	0.00253	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITGAL—hematologic cancer	4.37e-05	0.00253	CbGpPWpGaD
Melphalan—SLC7A5—Desoximetasone—Prednisolone—hematologic cancer	4.36e-05	0.0465	CbGdCrCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—FXYD6—hematologic cancer	4.27e-05	0.00247	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—RAC2—hematologic cancer	4.15e-05	0.0024	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCC3—hematologic cancer	4.1e-05	0.00237	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—SRC—hematologic cancer	3.93e-05	0.00228	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—NRAS—hematologic cancer	3.78e-05	0.00219	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SH2B3—hematologic cancer	3.76e-05	0.00218	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	3.76e-05	0.00217	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	3.75e-05	0.00217	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SPARC—hematologic cancer	3.59e-05	0.00208	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—NUP98—hematologic cancer	3.55e-05	0.00205	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—NUP98—hematologic cancer	3.54e-05	0.00205	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—S100A10—hematologic cancer	3.48e-05	0.00202	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—LCK—hematologic cancer	3.47e-05	0.00201	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ADCY7—hematologic cancer	3.43e-05	0.00199	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—NUP214—hematologic cancer	3.42e-05	0.00198	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—NUP214—hematologic cancer	3.41e-05	0.00197	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—H3F3A—hematologic cancer	3.41e-05	0.00197	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GATA3—hematologic cancer	3.37e-05	0.00195	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HSPA5—hematologic cancer	3.36e-05	0.00194	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCG2—hematologic cancer	3.34e-05	0.00193	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PRKCZ—hematologic cancer	3.31e-05	0.00192	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—KRAS—hematologic cancer	3.26e-05	0.00188	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	3.24e-05	0.00188	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HDAC2—hematologic cancer	3.08e-05	0.00179	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ITGA4—hematologic cancer	3.05e-05	0.00177	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CD44—hematologic cancer	3.05e-05	0.00177	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	3.05e-05	0.00176	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—PIK3CA—hematologic cancer	2.99e-05	0.00173	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—TFRC—hematologic cancer	2.98e-05	0.00172	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL3—hematologic cancer	2.97e-05	0.00172	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IFNA1—hematologic cancer	2.95e-05	0.00171	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PTPN1—hematologic cancer	2.92e-05	0.00169	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	2.89e-05	0.00167	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—RASGRP1—hematologic cancer	2.88e-05	0.00167	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SYK—hematologic cancer	2.87e-05	0.00166	CbGpPWpGaD
Melphalan—SLC7A5—Cell surface interactions at the vascular wall—HRAS—hematologic cancer	2.77e-05	0.0016	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IFNA2—hematologic cancer	2.75e-05	0.00159	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ATP4A—hematologic cancer	2.64e-05	0.00153	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ANXA2—hematologic cancer	2.64e-05	0.00153	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SGK1—hematologic cancer	2.64e-05	0.00153	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—GRB2—hematologic cancer	2.59e-05	0.0015	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PDGFA—hematologic cancer	2.58e-05	0.00149	CbGpPWpGaD
Melphalan—SLC7A5—SLC-mediated transmembrane transport—ALB—hematologic cancer	2.57e-05	0.00149	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—CYCS—hematologic cancer	2.5e-05	0.00145	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ABL1—hematologic cancer	2.49e-05	0.00144	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	2.38e-05	0.00138	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PHYH—hematologic cancer	2.35e-05	0.00136	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GMPS—hematologic cancer	2.35e-05	0.00136	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—FTCD—hematologic cancer	2.35e-05	0.00136	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HGF—hematologic cancer	2.34e-05	0.00135	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CSF2—hematologic cancer	2.31e-05	0.00134	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PRKCG—hematologic cancer	2.23e-05	0.00129	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—JAK1—hematologic cancer	2.23e-05	0.00129	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SMPD3—hematologic cancer	2.15e-05	0.00125	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCC3—hematologic cancer	2.09e-05	0.00121	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ABCB1—hematologic cancer	2.08e-05	0.00121	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL2RA—hematologic cancer	2.08e-05	0.00121	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PDGFB—hematologic cancer	2.01e-05	0.00116	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CDK2—hematologic cancer	1.95e-05	0.00113	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	1.91e-05	0.00111	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ASNS—hematologic cancer	1.88e-05	0.00109	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—DCK—hematologic cancer	1.88e-05	0.00109	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—B3GAT1—hematologic cancer	1.88e-05	0.00109	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MAPK14—hematologic cancer	1.87e-05	0.00108	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—FN1—hematologic cancer	1.81e-05	0.00105	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—NUP98—hematologic cancer	1.8e-05	0.00104	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HDC—hematologic cancer	1.78e-05	0.00103	CbGpPWpGaD
Melphalan—Ibuprofen—ALB—hematologic cancer	1.76e-05	0.0145	CrCbGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ADCY7—hematologic cancer	1.75e-05	0.00101	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—NUP214—hematologic cancer	1.74e-05	0.00101	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CG—hematologic cancer	1.74e-05	0.001	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PTPN11—hematologic cancer	1.71e-05	0.000987	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCG2—hematologic cancer	1.7e-05	0.000985	CbGpPWpGaD
Melphalan—Ibuprofen—ABCB1—hematologic cancer	1.68e-05	0.0139	CrCbGaD
Melphalan—SLC22A3—Metabolism—CDA—hematologic cancer	1.63e-05	0.000945	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—CREBBP—hematologic cancer	1.61e-05	0.000932	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PC—hematologic cancer	1.57e-05	0.000909	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CD—hematologic cancer	1.53e-05	0.000883	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GBA—hematologic cancer	1.52e-05	0.000878	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC35B2—hematologic cancer	1.52e-05	0.000878	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—TFRC—hematologic cancer	1.52e-05	0.000878	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—ALB—hematologic cancer	1.51e-05	0.000872	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3R1—hematologic cancer	1.44e-05	0.000834	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—JAK2—hematologic cancer	1.4e-05	0.000811	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.39e-05	0.000807	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—MTAP—hematologic cancer	1.39e-05	0.000803	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CB—hematologic cancer	1.33e-05	0.00077	CbGpPWpGaD
Melphalan—SLC22A3—SLC-mediated transmembrane transport—ALB—hematologic cancer	1.31e-05	0.000757	CbGpPWpGaD
Melphalan—SLC7A5—Transmembrane transport of small molecules—ALB—hematologic cancer	1.3e-05	0.000755	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.27e-05	0.000737	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—FHL2—hematologic cancer	1.24e-05	0.000716	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—IL2—hematologic cancer	1.22e-05	0.000707	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—AGRN—hematologic cancer	1.21e-05	0.000702	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—IDH2—hematologic cancer	1.15e-05	0.000666	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—HMMR—hematologic cancer	1.15e-05	0.000666	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—EP300—hematologic cancer	1.1e-05	0.000635	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ARNTL—hematologic cancer	1.08e-05	0.000626	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—SRC—hematologic cancer	1.07e-05	0.000617	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.06e-05	0.000615	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ACP5—hematologic cancer	1.05e-05	0.000609	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CA9—hematologic cancer	1.05e-05	0.000609	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—VEGFA—hematologic cancer	1.04e-05	0.000601	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NCOR2—hematologic cancer	1.04e-05	0.000601	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—NRAS—hematologic cancer	1.03e-05	0.000594	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—IDH1—hematologic cancer	9.89e-06	0.000572	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—MAPK3—hematologic cancer	9.82e-06	0.000569	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—TXN—hematologic cancer	9.78e-06	0.000566	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTO1—hematologic cancer	9.78e-06	0.000566	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ABCC3—hematologic cancer	9.78e-06	0.000566	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SPHK1—hematologic cancer	9.57e-06	0.000554	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TGFB1—hematologic cancer	9.53e-06	0.000552	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—UGT1A1—hematologic cancer	9.19e-06	0.000532	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SLC22A1—hematologic cancer	8.94e-06	0.000518	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—CRABP1—hematologic cancer	8.94e-06	0.000518	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—KRAS—hematologic cancer	8.83e-06	0.000511	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ALOX5—hematologic cancer	8.71e-06	0.000504	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NUP98—hematologic cancer	8.44e-06	0.000489	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ADCY7—hematologic cancer	8.19e-06	0.000474	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NCOA3—hematologic cancer	8.19e-06	0.000474	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NUP214—hematologic cancer	8.13e-06	0.000471	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—PIK3CA—hematologic cancer	8.11e-06	0.000469	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—MTR—hematologic cancer	7.97e-06	0.000461	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ABCG2—hematologic cancer	7.97e-06	0.000461	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—TP53—hematologic cancer	7.84e-06	0.000454	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—ENO2—hematologic cancer	7.82e-06	0.000452	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—GSTT1—hematologic cancer	7.58e-06	0.000439	CbGpPWpGaD
Melphalan—SLC7A5—Hemostasis—HRAS—hematologic cancer	7.5e-06	0.000434	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—SDC1—hematologic cancer	7.41e-06	0.000429	CbGpPWpGaD
Melphalan—SLC22A3—Transmembrane transport of small molecules—CREBBP—hematologic cancer	7.1e-06	0.000411	CbGpPWpGaD
Melphalan—Infection—Dexamethasone—hematologic cancer	6.73e-06	9.72e-05	CcSEcCtD
Melphalan—Infection—Betamethasone—hematologic cancer	6.73e-06	9.72e-05	CcSEcCtD
Melphalan—Rash—Carmustine—hematologic cancer	6.71e-06	9.69e-05	CcSEcCtD
Melphalan—Dermatitis—Carmustine—hematologic cancer	6.71e-06	9.68e-05	CcSEcCtD
Melphalan—Vomiting—Alitretinoin—hematologic cancer	6.71e-06	9.68e-05	CcSEcCtD
Melphalan—Paraesthesia—Triamcinolone—hematologic cancer	6.7e-06	9.68e-05	CcSEcCtD
Melphalan—Anaemia—Prednisone—hematologic cancer	6.68e-06	9.65e-05	CcSEcCtD
Melphalan—Dyspnoea—Triamcinolone—hematologic cancer	6.66e-06	9.61e-05	CcSEcCtD
Melphalan—Rash—Alitretinoin—hematologic cancer	6.65e-06	9.6e-05	CcSEcCtD
Melphalan—Dermatitis—Alitretinoin—hematologic cancer	6.64e-06	9.59e-05	CcSEcCtD
Melphalan—SLC22A3—Transmembrane transport of small molecules—ALB—hematologic cancer	6.64e-06	0.000385	CbGpPWpGaD
Melphalan—Thrombocytopenia—Dexamethasone—hematologic cancer	6.63e-06	9.58e-05	CcSEcCtD
Melphalan—Thrombocytopenia—Betamethasone—hematologic cancer	6.63e-06	9.58e-05	CcSEcCtD
Melphalan—Vomiting—Ifosfamide—hematologic cancer	6.63e-06	9.57e-05	CcSEcCtD
Melphalan—SLC7A5—Hemostasis—AKT1—hematologic cancer	6.62e-06	0.000383	CbGpPWpGaD
Melphalan—Hypersensitivity—Cisplatin—hematologic cancer	6.62e-06	9.56e-05	CcSEcCtD
Melphalan—Tachycardia—Betamethasone—hematologic cancer	6.61e-06	9.54e-05	CcSEcCtD
Melphalan—Tachycardia—Dexamethasone—hematologic cancer	6.61e-06	9.54e-05	CcSEcCtD
Melphalan—Diarrhoea—Gemcitabine—hematologic cancer	6.6e-06	9.52e-05	CcSEcCtD
Melphalan—Nausea—Thalidomide—hematologic cancer	6.58e-06	9.5e-05	CcSEcCtD
Melphalan—Dyspepsia—Triamcinolone—hematologic cancer	6.57e-06	9.49e-05	CcSEcCtD
Melphalan—Rash—Ifosfamide—hematologic cancer	6.57e-06	9.49e-05	CcSEcCtD
Melphalan—Dermatitis—Ifosfamide—hematologic cancer	6.57e-06	9.48e-05	CcSEcCtD
Melphalan—Neuropathy peripheral—Doxorubicin—hematologic cancer	6.56e-06	9.47e-05	CcSEcCtD
Melphalan—Urticaria—Etoposide—hematologic cancer	6.54e-06	9.44e-05	CcSEcCtD
Melphalan—Haemoglobin—Epirubicin—hematologic cancer	6.53e-06	9.42e-05	CcSEcCtD
Melphalan—Jaundice—Doxorubicin—hematologic cancer	6.53e-06	9.42e-05	CcSEcCtD
Melphalan—Stomatitis—Doxorubicin—hematologic cancer	6.53e-06	9.42e-05	CcSEcCtD
Melphalan—Hepatitis—Epirubicin—hematologic cancer	6.5e-06	9.38e-05	CcSEcCtD
Melphalan—Haemorrhage—Epirubicin—hematologic cancer	6.5e-06	9.38e-05	CcSEcCtD
Melphalan—Vomiting—Vincristine—hematologic cancer	6.46e-06	9.33e-05	CcSEcCtD
Melphalan—Anorexia—Dexamethasone—hematologic cancer	6.46e-06	9.32e-05	CcSEcCtD
Melphalan—Anorexia—Betamethasone—hematologic cancer	6.46e-06	9.32e-05	CcSEcCtD
Melphalan—Urticaria—Prednisolone—hematologic cancer	6.45e-06	9.31e-05	CcSEcCtD
Melphalan—Asthenia—Cisplatin—hematologic cancer	6.45e-06	9.31e-05	CcSEcCtD
Melphalan—Fatigue—Triamcinolone—hematologic cancer	6.44e-06	9.29e-05	CcSEcCtD
Melphalan—Urinary tract disorder—Epirubicin—hematologic cancer	6.41e-06	9.26e-05	CcSEcCtD
Melphalan—Rash—Vincristine—hematologic cancer	6.41e-06	9.25e-05	CcSEcCtD
Melphalan—Dermatitis—Vincristine—hematologic cancer	6.4e-06	9.24e-05	CcSEcCtD
Melphalan—Pain—Triamcinolone—hematologic cancer	6.39e-06	9.22e-05	CcSEcCtD
Melphalan—Connective tissue disorder—Epirubicin—hematologic cancer	6.38e-06	9.21e-05	CcSEcCtD
Melphalan—Urethral disorder—Epirubicin—hematologic cancer	6.37e-06	9.19e-05	CcSEcCtD
Melphalan—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.33e-06	9.14e-05	CcSEcCtD
Melphalan—Hypotension—Betamethasone—hematologic cancer	6.33e-06	9.14e-05	CcSEcCtD
Melphalan—Hypotension—Dexamethasone—hematologic cancer	6.33e-06	9.14e-05	CcSEcCtD
Melphalan—Nausea—Carmustine—hematologic cancer	6.32e-06	9.13e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CD44—hematologic cancer	6.3e-06	0.000365	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NQO1—hematologic cancer	6.3e-06	0.000365	CbGpPWpGaD
Melphalan—Vomiting—Irinotecan—hematologic cancer	6.29e-06	9.08e-05	CcSEcCtD
Melphalan—Vomiting—Mitoxantrone—hematologic cancer	6.29e-06	9.08e-05	CcSEcCtD
Melphalan—Immune system disorder—Methotrexate—hematologic cancer	6.27e-06	9.05e-05	CcSEcCtD
Melphalan—Nausea—Alitretinoin—hematologic cancer	6.26e-06	9.04e-05	CcSEcCtD
Melphalan—Convulsion—Prednisone—hematologic cancer	6.26e-06	9.04e-05	CcSEcCtD
Melphalan—Mediastinal disorder—Methotrexate—hematologic cancer	6.25e-06	9.03e-05	CcSEcCtD
Melphalan—Rash—Mitoxantrone—hematologic cancer	6.24e-06	9.01e-05	CcSEcCtD
Melphalan—Rash—Irinotecan—hematologic cancer	6.24e-06	9.01e-05	CcSEcCtD
Melphalan—Dermatitis—Irinotecan—hematologic cancer	6.23e-06	9e-05	CcSEcCtD
Melphalan—Dermatitis—Mitoxantrone—hematologic cancer	6.23e-06	9e-05	CcSEcCtD
Melphalan—Nausea—Ifosfamide—hematologic cancer	6.19e-06	8.94e-05	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Betamethasone—hematologic cancer	6.17e-06	8.91e-05	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	6.17e-06	8.91e-05	CcSEcCtD
Melphalan—Myalgia—Prednisone—hematologic cancer	6.15e-06	8.88e-05	CcSEcCtD
Melphalan—Diarrhoea—Cisplatin—hematologic cancer	6.15e-06	8.87e-05	CcSEcCtD
Melphalan—Alopecia—Methotrexate—hematologic cancer	6.13e-06	8.85e-05	CcSEcCtD
Melphalan—Vomiting—Gemcitabine—hematologic cancer	6.13e-06	8.85e-05	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.11e-06	8.82e-05	CcSEcCtD
Melphalan—Paraesthesia—Betamethasone—hematologic cancer	6.08e-06	8.78e-05	CcSEcCtD
Melphalan—Paraesthesia—Dexamethasone—hematologic cancer	6.08e-06	8.78e-05	CcSEcCtD
Melphalan—Rash—Gemcitabine—hematologic cancer	6.08e-06	8.77e-05	CcSEcCtD
Melphalan—Dermatitis—Gemcitabine—hematologic cancer	6.07e-06	8.77e-05	CcSEcCtD
Melphalan—Hypersensitivity—Etoposide—hematologic cancer	6.06e-06	8.76e-05	CcSEcCtD
Melphalan—Haemoglobin—Doxorubicin—hematologic cancer	6.04e-06	8.72e-05	CcSEcCtD
Melphalan—Nausea—Vincristine—hematologic cancer	6.04e-06	8.71e-05	CcSEcCtD
Melphalan—Flushing—Epirubicin—hematologic cancer	6.03e-06	8.7e-05	CcSEcCtD
Melphalan—Hepatitis—Doxorubicin—hematologic cancer	6.01e-06	8.68e-05	CcSEcCtD
Melphalan—Haemorrhage—Doxorubicin—hematologic cancer	6.01e-06	8.68e-05	CcSEcCtD
Melphalan—Hypersensitivity—Prednisolone—hematologic cancer	5.98e-06	8.64e-05	CcSEcCtD
Melphalan—Dyspepsia—Dexamethasone—hematologic cancer	5.96e-06	8.61e-05	CcSEcCtD
Melphalan—Dyspepsia—Betamethasone—hematologic cancer	5.96e-06	8.61e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CYCS—hematologic cancer	5.96e-06	0.000345	CbGpPWpGaD
Melphalan—Urinary tract disorder—Doxorubicin—hematologic cancer	5.93e-06	8.57e-05	CcSEcCtD
Melphalan—Urticaria—Triamcinolone—hematologic cancer	5.93e-06	8.56e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—HSP90AA1—hematologic cancer	5.92e-06	0.000343	CbGpPWpGaD
Melphalan—Asthenia—Etoposide—hematologic cancer	5.91e-06	8.53e-05	CcSEcCtD
Melphalan—Connective tissue disorder—Doxorubicin—hematologic cancer	5.91e-06	8.53e-05	CcSEcCtD
Melphalan—Anaphylactic shock—Prednisone—hematologic cancer	5.9e-06	8.52e-05	CcSEcCtD
Melphalan—Oedema—Prednisone—hematologic cancer	5.9e-06	8.52e-05	CcSEcCtD
Melphalan—Urethral disorder—Doxorubicin—hematologic cancer	5.89e-06	8.5e-05	CcSEcCtD
Melphalan—Decreased appetite—Betamethasone—hematologic cancer	5.89e-06	8.5e-05	CcSEcCtD
Melphalan—Decreased appetite—Dexamethasone—hematologic cancer	5.89e-06	8.5e-05	CcSEcCtD
Melphalan—Nausea—Irinotecan—hematologic cancer	5.88e-06	8.49e-05	CcSEcCtD
Melphalan—Nausea—Mitoxantrone—hematologic cancer	5.88e-06	8.49e-05	CcSEcCtD
Melphalan—Immune system disorder—Epirubicin—hematologic cancer	5.87e-06	8.47e-05	CcSEcCtD
Melphalan—Infection—Prednisone—hematologic cancer	5.86e-06	8.46e-05	CcSEcCtD
Melphalan—Mediastinal disorder—Epirubicin—hematologic cancer	5.85e-06	8.45e-05	CcSEcCtD
Melphalan—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.85e-06	8.44e-05	CcSEcCtD
Melphalan—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.85e-06	8.44e-05	CcSEcCtD
Melphalan—Fatigue—Betamethasone—hematologic cancer	5.84e-06	8.43e-05	CcSEcCtD
Melphalan—Fatigue—Dexamethasone—hematologic cancer	5.84e-06	8.43e-05	CcSEcCtD
Melphalan—Pruritus—Etoposide—hematologic cancer	5.82e-06	8.41e-05	CcSEcCtD
Melphalan—Arrhythmia—Epirubicin—hematologic cancer	5.8e-06	8.38e-05	CcSEcCtD
Melphalan—Pain—Dexamethasone—hematologic cancer	5.79e-06	8.36e-05	CcSEcCtD
Melphalan—Pain—Betamethasone—hematologic cancer	5.79e-06	8.36e-05	CcSEcCtD
Melphalan—Tachycardia—Prednisone—hematologic cancer	5.76e-06	8.31e-05	CcSEcCtD
Melphalan—Alopecia—Epirubicin—hematologic cancer	5.74e-06	8.29e-05	CcSEcCtD
Melphalan—Skin disorder—Prednisone—hematologic cancer	5.73e-06	8.27e-05	CcSEcCtD
Melphalan—Nausea—Gemcitabine—hematologic cancer	5.73e-06	8.27e-05	CcSEcCtD
Melphalan—Vomiting—Cisplatin—hematologic cancer	5.71e-06	8.25e-05	CcSEcCtD
Melphalan—Rash—Cisplatin—hematologic cancer	5.67e-06	8.18e-05	CcSEcCtD
Melphalan—Dermatitis—Cisplatin—hematologic cancer	5.66e-06	8.17e-05	CcSEcCtD
Melphalan—Diarrhoea—Etoposide—hematologic cancer	5.63e-06	8.13e-05	CcSEcCtD
Melphalan—Anorexia—Prednisone—hematologic cancer	5.62e-06	8.12e-05	CcSEcCtD
Melphalan—Anaemia—Methotrexate—hematologic cancer	5.58e-06	8.06e-05	CcSEcCtD
Melphalan—Flushing—Doxorubicin—hematologic cancer	5.58e-06	8.05e-05	CcSEcCtD
Melphalan—Hypersensitivity—Triamcinolone—hematologic cancer	5.5e-06	7.94e-05	CcSEcCtD
Melphalan—Immune system disorder—Doxorubicin—hematologic cancer	5.43e-06	7.84e-05	CcSEcCtD
Melphalan—Mediastinal disorder—Doxorubicin—hematologic cancer	5.42e-06	7.82e-05	CcSEcCtD
Melphalan—Leukopenia—Methotrexate—hematologic cancer	5.41e-06	7.81e-05	CcSEcCtD
Melphalan—Urticaria—Betamethasone—hematologic cancer	5.38e-06	7.77e-05	CcSEcCtD
Melphalan—Urticaria—Dexamethasone—hematologic cancer	5.38e-06	7.77e-05	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Prednisone—hematologic cancer	5.38e-06	7.76e-05	CcSEcCtD
Melphalan—Arrhythmia—Doxorubicin—hematologic cancer	5.37e-06	7.75e-05	CcSEcCtD
Melphalan—Asthenia—Triamcinolone—hematologic cancer	5.36e-06	7.73e-05	CcSEcCtD
Melphalan—Nausea—Cisplatin—hematologic cancer	5.34e-06	7.7e-05	CcSEcCtD
Melphalan—Alopecia—Doxorubicin—hematologic cancer	5.31e-06	7.67e-05	CcSEcCtD
Melphalan—Paraesthesia—Prednisone—hematologic cancer	5.3e-06	7.65e-05	CcSEcCtD
Melphalan—Pruritus—Triamcinolone—hematologic cancer	5.28e-06	7.63e-05	CcSEcCtD
Melphalan—Cough—Methotrexate—hematologic cancer	5.27e-06	7.61e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—GSTP1—hematologic cancer	5.25e-06	0.000304	CbGpPWpGaD
Melphalan—Convulsion—Methotrexate—hematologic cancer	5.23e-06	7.56e-05	CcSEcCtD
Melphalan—Vomiting—Etoposide—hematologic cancer	5.23e-06	7.56e-05	CcSEcCtD
Melphalan—Anaemia—Epirubicin—hematologic cancer	5.23e-06	7.54e-05	CcSEcCtD
Melphalan—Dyspepsia—Prednisone—hematologic cancer	5.19e-06	7.5e-05	CcSEcCtD
Melphalan—Rash—Etoposide—hematologic cancer	5.19e-06	7.49e-05	CcSEcCtD
Melphalan—Dermatitis—Etoposide—hematologic cancer	5.19e-06	7.49e-05	CcSEcCtD
Melphalan—Myalgia—Methotrexate—hematologic cancer	5.14e-06	7.43e-05	CcSEcCtD
Melphalan—Chest pain—Methotrexate—hematologic cancer	5.14e-06	7.43e-05	CcSEcCtD
Melphalan—Decreased appetite—Prednisone—hematologic cancer	5.13e-06	7.4e-05	CcSEcCtD
Melphalan—Rash—Prednisolone—hematologic cancer	5.12e-06	7.39e-05	CcSEcCtD
Melphalan—Dermatitis—Prednisolone—hematologic cancer	5.11e-06	7.38e-05	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.11e-06	7.37e-05	CcSEcCtD
Melphalan—Fatigue—Prednisone—hematologic cancer	5.09e-06	7.34e-05	CcSEcCtD
Melphalan—Leukopenia—Epirubicin—hematologic cancer	5.06e-06	7.31e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ABCB1—hematologic cancer	4.97e-06	0.000288	CbGpPWpGaD
Melphalan—Cough—Epirubicin—hematologic cancer	4.93e-06	7.12e-05	CcSEcCtD
Melphalan—Anaphylactic shock—Methotrexate—hematologic cancer	4.93e-06	7.12e-05	CcSEcCtD
Melphalan—Convulsion—Epirubicin—hematologic cancer	4.9e-06	7.07e-05	CcSEcCtD
Melphalan—Infection—Methotrexate—hematologic cancer	4.9e-06	7.07e-05	CcSEcCtD
Melphalan—Nausea—Etoposide—hematologic cancer	4.89e-06	7.06e-05	CcSEcCtD
Melphalan—Asthenia—Betamethasone—hematologic cancer	4.86e-06	7.02e-05	CcSEcCtD
Melphalan—Asthenia—Dexamethasone—hematologic cancer	4.86e-06	7.02e-05	CcSEcCtD
Melphalan—Anaemia—Doxorubicin—hematologic cancer	4.84e-06	6.98e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—GSTM1—hematologic cancer	4.83e-06	0.00028	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—NCOR1—hematologic cancer	4.83e-06	0.00028	CbGpPWpGaD
Melphalan—Thrombocytopenia—Methotrexate—hematologic cancer	4.83e-06	6.97e-05	CcSEcCtD
Melphalan—Nausea—Prednisolone—hematologic cancer	4.82e-06	6.96e-05	CcSEcCtD
Melphalan—Myalgia—Epirubicin—hematologic cancer	4.81e-06	6.95e-05	CcSEcCtD
Melphalan—Chest pain—Epirubicin—hematologic cancer	4.81e-06	6.95e-05	CcSEcCtD
Melphalan—Pruritus—Dexamethasone—hematologic cancer	4.79e-06	6.92e-05	CcSEcCtD
Melphalan—Pruritus—Betamethasone—hematologic cancer	4.79e-06	6.92e-05	CcSEcCtD
Melphalan—Skin disorder—Methotrexate—hematologic cancer	4.79e-06	6.91e-05	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.78e-06	6.9e-05	CcSEcCtD
Melphalan—Vomiting—Triamcinolone—hematologic cancer	4.75e-06	6.85e-05	CcSEcCtD
Melphalan—Rash—Triamcinolone—hematologic cancer	4.71e-06	6.8e-05	CcSEcCtD
Melphalan—Dermatitis—Triamcinolone—hematologic cancer	4.7e-06	6.79e-05	CcSEcCtD
Melphalan—Anorexia—Methotrexate—hematologic cancer	4.7e-06	6.78e-05	CcSEcCtD
Melphalan—Urticaria—Prednisone—hematologic cancer	4.69e-06	6.77e-05	CcSEcCtD
Melphalan—Leukopenia—Doxorubicin—hematologic cancer	4.68e-06	6.76e-05	CcSEcCtD
Melphalan—Diarrhoea—Dexamethasone—hematologic cancer	4.64e-06	6.69e-05	CcSEcCtD
Melphalan—Diarrhoea—Betamethasone—hematologic cancer	4.64e-06	6.69e-05	CcSEcCtD
Melphalan—Anaphylactic shock—Epirubicin—hematologic cancer	4.61e-06	6.66e-05	CcSEcCtD
Melphalan—Oedema—Epirubicin—hematologic cancer	4.61e-06	6.66e-05	CcSEcCtD
Melphalan—Hypotension—Methotrexate—hematologic cancer	4.61e-06	6.65e-05	CcSEcCtD
Melphalan—Infection—Epirubicin—hematologic cancer	4.58e-06	6.62e-05	CcSEcCtD
Melphalan—Cough—Doxorubicin—hematologic cancer	4.57e-06	6.59e-05	CcSEcCtD
Melphalan—Convulsion—Doxorubicin—hematologic cancer	4.53e-06	6.54e-05	CcSEcCtD
Melphalan—Thrombocytopenia—Epirubicin—hematologic cancer	4.52e-06	6.52e-05	CcSEcCtD
Melphalan—Tachycardia—Epirubicin—hematologic cancer	4.5e-06	6.5e-05	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Methotrexate—hematologic cancer	4.49e-06	6.48e-05	CcSEcCtD
Melphalan—Skin disorder—Epirubicin—hematologic cancer	4.48e-06	6.47e-05	CcSEcCtD
Melphalan—Myalgia—Doxorubicin—hematologic cancer	4.45e-06	6.43e-05	CcSEcCtD
Melphalan—Chest pain—Doxorubicin—hematologic cancer	4.45e-06	6.43e-05	CcSEcCtD
Melphalan—Nausea—Triamcinolone—hematologic cancer	4.44e-06	6.4e-05	CcSEcCtD
Melphalan—Paraesthesia—Methotrexate—hematologic cancer	4.43e-06	6.39e-05	CcSEcCtD
Melphalan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.42e-06	6.39e-05	CcSEcCtD
Melphalan—Anorexia—Epirubicin—hematologic cancer	4.4e-06	6.35e-05	CcSEcCtD
Melphalan—Dyspnoea—Methotrexate—hematologic cancer	4.4e-06	6.35e-05	CcSEcCtD
Melphalan—Hypersensitivity—Prednisone—hematologic cancer	4.35e-06	6.27e-05	CcSEcCtD
Melphalan—Dyspepsia—Methotrexate—hematologic cancer	4.34e-06	6.27e-05	CcSEcCtD
Melphalan—Hypotension—Epirubicin—hematologic cancer	4.31e-06	6.22e-05	CcSEcCtD
Melphalan—Vomiting—Dexamethasone—hematologic cancer	4.31e-06	6.22e-05	CcSEcCtD
Melphalan—Vomiting—Betamethasone—hematologic cancer	4.31e-06	6.22e-05	CcSEcCtD
Melphalan—Decreased appetite—Methotrexate—hematologic cancer	4.29e-06	6.19e-05	CcSEcCtD
Melphalan—Rash—Betamethasone—hematologic cancer	4.27e-06	6.17e-05	CcSEcCtD
Melphalan—Rash—Dexamethasone—hematologic cancer	4.27e-06	6.17e-05	CcSEcCtD
Melphalan—Oedema—Doxorubicin—hematologic cancer	4.27e-06	6.16e-05	CcSEcCtD
Melphalan—Anaphylactic shock—Doxorubicin—hematologic cancer	4.27e-06	6.16e-05	CcSEcCtD
Melphalan—Dermatitis—Betamethasone—hematologic cancer	4.27e-06	6.16e-05	CcSEcCtD
Melphalan—Dermatitis—Dexamethasone—hematologic cancer	4.27e-06	6.16e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—MTHFR—hematologic cancer	4.27e-06	0.000247	CbGpPWpGaD
Melphalan—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.26e-06	6.15e-05	CcSEcCtD
Melphalan—Fatigue—Methotrexate—hematologic cancer	4.25e-06	6.14e-05	CcSEcCtD
Melphalan—Infection—Doxorubicin—hematologic cancer	4.24e-06	6.12e-05	CcSEcCtD
Melphalan—Asthenia—Prednisone—hematologic cancer	4.23e-06	6.11e-05	CcSEcCtD
Melphalan—Pain—Methotrexate—hematologic cancer	4.22e-06	6.09e-05	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Epirubicin—hematologic cancer	4.2e-06	6.07e-05	CcSEcCtD
Melphalan—Thrombocytopenia—Doxorubicin—hematologic cancer	4.18e-06	6.03e-05	CcSEcCtD
Melphalan—Pruritus—Prednisone—hematologic cancer	4.17e-06	6.03e-05	CcSEcCtD
Melphalan—Tachycardia—Doxorubicin—hematologic cancer	4.17e-06	6.02e-05	CcSEcCtD
Melphalan—Skin disorder—Doxorubicin—hematologic cancer	4.15e-06	5.99e-05	CcSEcCtD
Melphalan—Paraesthesia—Epirubicin—hematologic cancer	4.14e-06	5.98e-05	CcSEcCtD
Melphalan—Dyspnoea—Epirubicin—hematologic cancer	4.11e-06	5.94e-05	CcSEcCtD
Melphalan—Anorexia—Doxorubicin—hematologic cancer	4.07e-06	5.88e-05	CcSEcCtD
Melphalan—Dyspepsia—Epirubicin—hematologic cancer	4.06e-06	5.86e-05	CcSEcCtD
Melphalan—Diarrhoea—Prednisone—hematologic cancer	4.04e-06	5.83e-05	CcSEcCtD
Melphalan—Nausea—Dexamethasone—hematologic cancer	4.02e-06	5.81e-05	CcSEcCtD
Melphalan—Nausea—Betamethasone—hematologic cancer	4.02e-06	5.81e-05	CcSEcCtD
Melphalan—Decreased appetite—Epirubicin—hematologic cancer	4.01e-06	5.79e-05	CcSEcCtD
Melphalan—Hypotension—Doxorubicin—hematologic cancer	3.99e-06	5.76e-05	CcSEcCtD
Melphalan—Gastrointestinal disorder—Epirubicin—hematologic cancer	3.98e-06	5.75e-05	CcSEcCtD
Melphalan—Fatigue—Epirubicin—hematologic cancer	3.98e-06	5.74e-05	CcSEcCtD
Melphalan—Pain—Epirubicin—hematologic cancer	3.95e-06	5.7e-05	CcSEcCtD
Melphalan—Urticaria—Methotrexate—hematologic cancer	3.92e-06	5.65e-05	CcSEcCtD
Melphalan—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	3.89e-06	5.62e-05	CcSEcCtD
Melphalan—Paraesthesia—Doxorubicin—hematologic cancer	3.83e-06	5.53e-05	CcSEcCtD
Melphalan—Dyspnoea—Doxorubicin—hematologic cancer	3.81e-06	5.49e-05	CcSEcCtD
Melphalan—Dyspepsia—Doxorubicin—hematologic cancer	3.76e-06	5.43e-05	CcSEcCtD
Melphalan—Vomiting—Prednisone—hematologic cancer	3.75e-06	5.42e-05	CcSEcCtD
Melphalan—Rash—Prednisone—hematologic cancer	3.72e-06	5.37e-05	CcSEcCtD
Melphalan—Dermatitis—Prednisone—hematologic cancer	3.72e-06	5.37e-05	CcSEcCtD
Melphalan—Decreased appetite—Doxorubicin—hematologic cancer	3.71e-06	5.36e-05	CcSEcCtD
Melphalan—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.69e-06	5.32e-05	CcSEcCtD
Melphalan—Fatigue—Doxorubicin—hematologic cancer	3.68e-06	5.31e-05	CcSEcCtD
Melphalan—Urticaria—Epirubicin—hematologic cancer	3.67e-06	5.29e-05	CcSEcCtD
Melphalan—Pain—Doxorubicin—hematologic cancer	3.65e-06	5.27e-05	CcSEcCtD
Melphalan—Hypersensitivity—Methotrexate—hematologic cancer	3.63e-06	5.24e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PIK3CG—hematologic cancer	3.59e-06	0.000208	CbGpPWpGaD
Melphalan—Asthenia—Methotrexate—hematologic cancer	3.54e-06	5.11e-05	CcSEcCtD
Melphalan—Nausea—Prednisone—hematologic cancer	3.5e-06	5.06e-05	CcSEcCtD
Melphalan—Pruritus—Methotrexate—hematologic cancer	3.49e-06	5.04e-05	CcSEcCtD
Melphalan—Hypersensitivity—Epirubicin—hematologic cancer	3.4e-06	4.91e-05	CcSEcCtD
Melphalan—Urticaria—Doxorubicin—hematologic cancer	3.39e-06	4.9e-05	CcSEcCtD
Melphalan—Diarrhoea—Methotrexate—hematologic cancer	3.37e-06	4.87e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—CREBBP—hematologic cancer	3.32e-06	0.000192	CbGpPWpGaD
Melphalan—Asthenia—Epirubicin—hematologic cancer	3.31e-06	4.78e-05	CcSEcCtD
Melphalan—Pruritus—Epirubicin—hematologic cancer	3.26e-06	4.71e-05	CcSEcCtD
Melphalan—Diarrhoea—Epirubicin—hematologic cancer	3.16e-06	4.56e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PIK3CD—hematologic cancer	3.15e-06	0.000182	CbGpPWpGaD
Melphalan—Hypersensitivity—Doxorubicin—hematologic cancer	3.15e-06	4.54e-05	CcSEcCtD
Melphalan—Vomiting—Methotrexate—hematologic cancer	3.14e-06	4.53e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—ALB—hematologic cancer	3.11e-06	0.00018	CbGpPWpGaD
Melphalan—Rash—Methotrexate—hematologic cancer	3.11e-06	4.49e-05	CcSEcCtD
Melphalan—Dermatitis—Methotrexate—hematologic cancer	3.11e-06	4.48e-05	CcSEcCtD
Melphalan—Asthenia—Doxorubicin—hematologic cancer	3.06e-06	4.42e-05	CcSEcCtD
Melphalan—Pruritus—Doxorubicin—hematologic cancer	3.02e-06	4.36e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PIK3R1—hematologic cancer	2.98e-06	0.000172	CbGpPWpGaD
Melphalan—Vomiting—Epirubicin—hematologic cancer	2.93e-06	4.24e-05	CcSEcCtD
Melphalan—Nausea—Methotrexate—hematologic cancer	2.93e-06	4.23e-05	CcSEcCtD
Melphalan—Diarrhoea—Doxorubicin—hematologic cancer	2.92e-06	4.22e-05	CcSEcCtD
Melphalan—Rash—Epirubicin—hematologic cancer	2.91e-06	4.2e-05	CcSEcCtD
Melphalan—Dermatitis—Epirubicin—hematologic cancer	2.91e-06	4.2e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PIK3CB—hematologic cancer	2.75e-06	0.000159	CbGpPWpGaD
Melphalan—Nausea—Epirubicin—hematologic cancer	2.74e-06	3.96e-05	CcSEcCtD
Melphalan—Vomiting—Doxorubicin—hematologic cancer	2.71e-06	3.92e-05	CcSEcCtD
Melphalan—Rash—Doxorubicin—hematologic cancer	2.69e-06	3.89e-05	CcSEcCtD
Melphalan—Dermatitis—Doxorubicin—hematologic cancer	2.69e-06	3.88e-05	CcSEcCtD
Melphalan—Nausea—Doxorubicin—hematologic cancer	2.54e-06	3.66e-05	CcSEcCtD
Melphalan—SLC22A3—Metabolism—PTEN—hematologic cancer	2.37e-06	0.000137	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—EP300—hematologic cancer	2.26e-06	0.000131	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—PIK3CA—hematologic cancer	1.67e-06	9.7e-05	CbGpPWpGaD
Melphalan—SLC22A3—Metabolism—AKT1—hematologic cancer	1.37e-06	7.92e-05	CbGpPWpGaD
